<DOC>
	<DOCNO>NCT00003614</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness paclitaxel plus estramustine treating patient metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Paclitaxel Plus Estramustine Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effect weekly paclitaxel plus estramustine PSA response patient metastatic hormone-refractory prostate cancer . II . Describe toxic effect treatment patient population . III . Determine effect treatment pain , asthenia , quality life . IV . Determine objective response rate treatment among patient bidimensionally measurable disease . OUTLINE : Patients receive estramustine orally twice day day 1-3 week 6 week . Patients also receive paclitaxel IV 1 hour day 2 week 6 week . Courses repeat every 8 week absence unacceptable toxicity disease progression . Quality life assess prior treatment week 4 , 8 , 20 , 24 . Patients follow every 3 month 2 year , every 6 month year 2-5 , annually thereafter . PROJECTED ACCRUAL : There 17-52 patient accrue study 14 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic hormonerefractory adenocarcinoma prostate gland Elevated serum acid phosphatase PSA level must evidence disease Must evidence progressive metastatic disease ( e.g. , bone , pelvic mass , lymph node , liver , lung metastasis ) Radiological evidence hydronephrosis alone constitute evidence metastatic disease Patients bone metastasis ( i.e. , lack measurable soft tissue disease ) must PSA level least 20 ng/mL Patients soft tissue metastasis and/or visceral disease must either bidimensionally measurable disease PSA level least 20 ng/mL Must prior treatment bilateral orchiectomy primary hormonal therapy ( e.g. , estrogen therapy , LHRHblocker plus flutamide , etc . ) evidence treatment failure No carcinomatous meningitis brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm3 OR Granulocyte count least 2,000/mm3 Platelet count great 100,000/mm3 No history deep venous thrombosis Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2 time normal Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : No active angina pectoris No known New York Heart Association class IIIV heart disease No history myocardial infarction last 6 month Other : No history prior malignancy except curatively treated disease free time period consider appropriate cure specific cancer No serious concurrent illness active infection Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy ( include neoadjuvant chemotherapy ) Endocrine therapy : See Disease Characteristics At least 6 week since prior bicalutamide At least 4 week since prior flutamide nilutamide Recovered prior toxicity endocrine therapy Radiotherapy : No prior strontium 89 , samarium 153 , radioisotope therapy At least 4 week since prior radiotherapy recover Surgery : See Disease Characteristics Recovered prior surgery</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>